|
Bronchiectasis
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Therefore, defective airway clearance of apoptotic cells in cystic fibrosis and bronchiectasis may be due to elastase-mediated cleavage of phosphatidylserine receptor on phagocytes and may contribute to ongoing airway inflammation.
|
11877474 |
2002 |
|
Cystic Fibrosis
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Therefore, defective airway clearance of apoptotic cells in cystic fibrosis and bronchiectasis may be due to elastase-mediated cleavage of phosphatidylserine receptor on phagocytes and may contribute to ongoing airway inflammation.
|
11877474 |
2002 |
|
Gingivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The periodontal classification was assessed with the periodontal screening index (PSR/PSI) allocated to the following parameters: 1) healthy; 2) gingivitis (PSR/PSI score 0 to 2, maximum one sextant score; 3) moderate periodontitis (>1 sextant PSR/PSI score 3, maximum one sextant score; or, 4) severe periodontitis (>1 sextant PSR/PSI score 4).
|
21405936 |
2011 |
|
Periodontitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The periodontal classification was assessed with the periodontal screening index (PSR/PSI) allocated to the following parameters: 1) healthy; 2) gingivitis (PSR/PSI score 0 to 2, maximum one sextant score; 3) moderate periodontitis (>1 sextant PSR/PSI score 3, maximum one sextant score; or, 4) severe periodontitis (>1 sextant PSR/PSI score 4).
|
21405936 |
2011 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
|
22621393 |
2012 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
|
22621393 |
2012 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
JMJD6 was expressed at highest levels in tumors associated with worse outcomes, including ER- and basal-like, Claudin-low, Her2-enriched, and ER+ Luminal B tumors.
|
22621393 |
2012 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In addition, knockdown of JMJD6 in invasive cell lines, such as MDA-MB231, decreased motility and invasion, whereas overexpression in MCF-7 cells slightly promoted motility but did not confer invasive growth.
|
22621393 |
2012 |
|
Periodontal Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Effects of smoking and genotype on the PSR index of periodontal disease in adults aged 18-49.
|
23066400 |
2012 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001).
|
23595221 |
2013 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001).
|
23595221 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis showed that the status of JMJD6 expression was an independent prognostic factor for lung adenocarcinoma patients.
|
23595221 |
2013 |
|
Iron deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effects similar to iron deficiency were generated by siRNA knockdown of either splicing factor U2AF(65) or Fe(II)- and 2-oxoglutarate-dependent dioxygenase Jumonji domain-containing protein 6 (Jmjd6), which interacts with U2AF(65) by lysyl-hydroxylation.
|
23787363 |
2013 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Malignant tumor of colon
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results reveal a novel posttranslational modification for p53 and support the pursuit of JMJD6 as a potential biomarker for colon cancer aggressiveness and a potential target for colon cancer intervention.
|
24667498 |
2014 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results reveal a novel posttranslational modification for p53 and support the pursuit of JMJD6 as a potential biomarker for colon cancer aggressiveness and a potential target for colon cancer intervention.
|
24667498 |
2014 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that PDGF-BB and JMJD6 regulate T cell function during chronic HBV infection and may provide insights for the treatment strategies for CHB patients.
|
25219359 |
2014 |
|
Complete atrioventricular block
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that PDGF-BB and JMJD6 regulate T cell function during chronic HBV infection and may provide insights for the treatment strategies for CHB patients.
|
25219359 |
2014 |
|
Hepatitis B, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of JMJD6 was reduced in T lymphocytes in chronic hepatitis B (CHB) patients, and this reduction in JMJD6 expression was associated with impaired T cell proliferation.
|
25219359 |
2014 |
|
Malignant neoplasm of breast
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Although JMJD6 displays anti-tumoral properties in cell lines, its expression in breast tumours may be a marker of poor prognosis, suggesting that its function could be altered in breast cancer.
|
25951181 |
2015 |
|
Breast Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Although JMJD6 displays anti-tumoral properties in cell lines, its expression in breast tumours may be a marker of poor prognosis, suggesting that its function could be altered in breast cancer.
|
25951181 |
2015 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
The analysis of JMJD6 expression in a cohort of breast tumour samples indicates that JMJD6 was highly expressed in aggressive breast tumours.
|
25951181 |
2015 |